News

KEYNOTE-355 suggests responders can pause chemo yet maintain survival on pembrolizumab; immune side effects are mostly mild and manageable.

A phase 1 study of actinium (²²⁵Ac) rhPSMA-10.1 injection in patients who have received prior lutetium-177 PSMA-targeted therapy has initiated dosing of patients with metastatic castration-resistant prostate cancer.

TRIPLEX finds thoracic radiotherapy with durvalumab chemo in ES-SCLC adds toxicity and deaths, without boosting survival.

FDA clears perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, boosting event-free and overall survival ahead of cystectomy.

SER-155 led to short-term improvement in diarrhea management in patients receiving immune checkpoint inhibitors.

The FDA approval was based on studies using an on-body injector to administer isatuximab easily.

Pegfilgrastim-pccg now carries the same indications as its reference product, Neulasta.

During a live event, Kristen M. Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.

FDA clears IND for UGN-501 oncolytic virus, launching phase 1 NMIBC trial to test intravesical safety and immune-driven tumor control.

The PTEN IHC CDx is a companion diagnostic approved by the FDA to determine patients' eligibility for capivasertib in metastatic prostate cancer.

Ateganosine (THIO) plus cemiplimab shows 90.5% disease control in heavily pretreated NSCLC in phase 2 THIO-101 trial interim data (NCT05208944).

The FDA set a PDUFA date of April 28, 2027 for approval of the gamma secretase inhibitor for progressing desmoid tumors.

In an interview, Melody Chang, MBA, RPh, BCOP, explains the work that went into ensuring access to bispecific antibodies across a network of community oncology practices.

During a live event, Bruna Pellini, MD, and participants discussed treatment sequencing and post progression management in patients with ROS1-positive advanced non–small cell lung cancer.

During a live event, Brittany Siontis, MD, discussed a case of a 50-year-old patient with an actively growing desmoid tumor.

CMS proposes deeper 340B drug payment cuts for hospitals, reshaping outpatient cancer economics, consolidation incentives, and patient cost-sharing.

The results jeopardize the accelerated approval of adagrasib plus cetuximab for KRAS G12C–mutated mCRC.

FDA issues Complete Response Letter for manganese chloride tetrahydrate (Orviglance), an oral liver MRI contrast agent for renal-impaired patients.

During a live event, Andrew Brunner, MD, and participants discussed second-line therapy selection in lower-risk MDS following ESA failure.

Building on these data, the ongoing phase 3 BATTMAN trial is exploring botensilimab plus balstilimab in refractory MSS mCRC.

A Type B meeting enabled progress toward initiation of US dosing in a phase 3 trial of a radioligand antibody-drug conjugate for metastatic castration-resistant prostate cancer.

Mature 13-year data show radiotherapy and temozolomide yield similar survival in low-grade glioma, but molecular subtype, not treatment order, predicts outcomes.

The next-generation KRAS G12C inhibitor improved survival vs the approved first-generation agents sotorasib and adagrasib.

Virtual behavioral health embedded in community oncology boosts access for Black patients and patients on Medicaid, easing distress and improving quality of life.

Genome sequencing speeds tumor mutation discovery, boosting targeted cancer therapies and cell/gene treatments while raising urgent questions about data ownership, reporting uncertainty, and ethics.

During a live event, Sikander Ailawadhi, MD, and participants discussed treatment selection for a patient with heavily pretreated multiple myeloma who was not a candidate for CAR T-cell therapy and had exhausted both BCMA and GPRC5D-targeted bispecific options.

The zoldonrasib data build on the recent historical breakthrough with daraxonrasib in PDAC.

ASCO 2026 data reshapes lung cancer care, highlighting durable ALK control, new EGFR options, bispecific first-line gains, and SCLC progress.